Cyclo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

false 0000922247 0000922247 2025-01-10 2025-01-10 0000922247 ctdh:CommonStockParValue0001PerShareCustomMember 2025-01-10 2025-01-10 0000922247 ctdh:WarrantsToPurchaseCommonStockCustomMember 2025-01-10 2025-01-10

 

 

 

 

 

Date of Report (Date of earliest event reported)

 

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

On January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for continued listing because it had not yet held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end.

 

Pursuant to the Nasdaq Listing Rules, the Company has 45 calendar days (until February 24, 2025) to submit a plan to regain compliance with the Nasdaq Listing Rules, and if the plan is accepted, Nasdaq may grant the Company an exception of up to 180 calendar days (until June 30, 2025) to regain compliance with the Nasdaq Listing Rules.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.